Austrianni

Austrianni is a private biotech company founded by the creators of the Trianni human antibody platform, focusing on combating tuberculosis and multidrug-resistant extraintestinal pathogenic E. coli infections. The company's core technology enables the isolation of fully human antibodies with extended CDR3 loops for better access to hidden bacterial targets. Austrianni is developing both therapeutic antibodies to treat infections and diagnostic tools for point-of-care testing, positioning itself at the intersection of infectious disease therapeutics and diagnostics.

The Trianni human antibody platform enables generation of fully human antibodies through V(D)J recombination and somatic hypermutation, with capability for extended CDR3 loops to access hidden bacterial epitopes.

Faces competition from large pharma (GSK, Janssen) and biotechs in TB therapeutics, and established diagnostic companies (Cepheid, Abbott) in TB testing. Differentiation through fully human antibody platform with extended CDR3 loops enabling access to hidden bacterial epitopes, plus dual focus on both therapeutics and diagnostics.